Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis

Managing Editor, In Vivo

London, UK
Lucie Ellis has been covering the ups and downs of the pharmaceutical industry since joining the Informa Pharma Intelligence team in 2012. Prior to being Managing Editor of In Vivo, Lucie was a Senior Editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo’s print and online editions and also contributes feature-length articles to the publication on the topics of leadership, R&D, innovation and more.
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

European Companies Are Now Being ‘Properly Funded’

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared to the $686m companies raised in 2018 overall. Silicon Valley Bank expects the European sector to be in “rude health” for the next two to three years at least, when it comes to accessing VC cash.

Business Strategies Commercial

C-Suite Snippets: Planning For The Future Cancer Market

In case you missed it: catch up with snippets from interviews published by In Vivo this week.

Market Access Research and Development Strategies

VC Playbook: Making Focus A Strategic Advantage

In this latest installment of In Vivo’s VC Playbook series, Robert Tansley, a partner at Cambridge Innovation Capital, explains the fund’s special arrangement in Cambridge, UK and how the young venture capital group expects to grow in the biotech sector – the imminent prospect of Brexit notwithstanding.

VC Playbook Strategy

What Does It Take To Launch And Lead An Oncology Biotech Today?

Oncolytic virus company Theolytics has emerged ready to raise a series A round and get its preclinical assets into human trials by 2021. CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be able to answer the cancer drug pricing conundrum.

Business Strategies C-Suite Speaks

C-Suite Snippets: Medtech Leaders

In case you missed it: catch up with snippets from interviews published by In Vivo this week. 

Business Strategies Medical Device

Get The Most Out Of Your Marketing Research

Esin Izat, a pharmaceutical marketing research expert, talks to In Vivo about how smaller companies can better utilize pre-launch marketing research and how approaches are changing to reflect new customer profiles and advances in technology.

Business Strategies Market Access
See All